An interventional study of 300 mg SC and 500 mg SC in Obesity, sponsored by Rutgers University. Completed at 1 site in United States. Open to participants aged 20 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by Rutgers University · Not applicable, Interventional, and Prevention
The purpose of this study is to determine whether an herb with known alpha-glucosidase inhibitor properties (Salacia Chinensis, SC), affects postprandial appetite ratings and glucose indices in overweight/obese individuals.
Subjects are randomly assigned (double blinded) to 300 mg SC, 500 mg SC or placebo using a cross-over design on three different days (1 month wash out). Subjects consuming a capsule containing placebo or treatment(s) are examined before and after a fixed breakfast meal (50% carbohydrate; 30% fat; 20% protein).
Subjective appetite sensations are rated using visual analog scales (VAS) for hunger, satiety, fullness, and prospective food intake. In addition, the desire for specific tastes is analyzed and measurements are taken twice before breakfast (fasting baseline). After baseline screening and blood draw, postprandial appetite and taste perception ratings and blood will be obtained at multiple time points during the 3 hour postprandial period (30, 60, 90, 120,180 min). Blood will be analyzed for glucose/insulin, gut peptides, and other markers in response to the meal.
6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.
This study's enrollment of 51 is below the median of 78 across 4,878 interventional studies indexed under Obesity.
Browse Obesity studies →Rutgers University is the lead sponsor of 28 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
300 mg Salacia Chinensis (SC). This will be compared to placebo.
Dietary Supplement: 300 mg SC
500 mg Salacia Chinensis (SC). This will be compared to placebo.
Dietary Supplement: 500 mg SC
The investigators will examine subjects before and during a 3 hour period after subjects consume a Placebo capsule and a fixed breakfast meal.
Dietary Supplement: Placebo
Salacia (T1) capsule given with breakfast (mixed meal tolerance test)
Salacia (T2) capsule given with breakfast (mixed meal tolerance test)
Placebo capsule given with breakfast (mixed meal tolerance test)
Appetite ratings (VAS) at either dose compared to placebo compared to placebo)
Visual analog scale (VAS)
Time frame: Change from Baseline and 3 hours
Glucose indices (at either dose vs placebo)
serum markers
Time frame: Change from Baseline and 3 hours
Taste perception (dose compared to placebo)
visual analog scale
Time frame: Change from Baseline and 3 hours
Appetite regulating hormones and other markers at either dose or placebo
blood
Time frame: Change from Baseline and 3 hours
Bone Turnover markers at either dose or placebo
blood
Time frame: Change from baseline over 3 hours
Plan to share: Undecided — rules/regulations would need to be confirmed
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rutgers University